Schmid John P. 4

What Happened

• John P. Schmid, a director of Design Therapeutics (DSGN), was granted a derivative award covering 30,000 shares on June 9, 2026. The reported acquisition price is $0.00, meaning no cash was paid as part of this grant. This is a grant/award (transaction code A), not a purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (filed two days after the transaction; appears timely).
• Amount and price: 30,000 shares; $0.00 per share (derivative award).
• Vesting: Shares vest in equal monthly installments over 12 months beginning June 9, 2026; the award will be fully vested on the date of the company’s next annual meeting of stockholders (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No immediate sale or cashless exercise noted — this is a grant/award for future vesting.

Context

• This filing documents a compensation/retention-type grant to a director. Derivative awards like this give a future right to shares subject to vesting conditions and do not necessarily indicate immediate market action by the insider. Grants are common for board compensation and should be interpreted as part of executive/director pay rather than as a direct buy or sell signal.